CDR2L

Across TCGA pan-cancer cohorts, CDR2L mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of CDR2L’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where CDR2L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CDR2L is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, PDAC, and LUAD are the cancer types where CDR2L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDR2L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	All	−0.151	<.001	5	view →
PDAC	Female	II,III,IV	+0.722	<.001	4	view →
LUAD	Male	III,IV	−0.291	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

CDR2L–LSCC

Open the LSCC breakdown →